NABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE

C. MORENO RAMOS, M.D. GIL SIERRA, C. MARTÍNEZ DÍAZ
HOSPITAL UNIVERSITARIO DE PUERTO REAL, FARMACIA HOSPITALARIA, CÁDIZ, ESPAÑA.

Background and importance
- Palliative systemic chemotherapy in pancreatic cancer (PC) can improve disease-related symptoms and prolong survival.
- The most used treatment regimens: nabpaclitaxel plus gemcitabine (GemNab) and FOLFIRINOX
- There are no studies that directly compare the two schemes making the choice empirical.

Aim and objectives
To assess the effectiveness and safety of GemNab versus FOLFIRINOX in metastatic PC.

Material and methods
A descriptive retrospective study January 2016 - September 2021
- Variables: age, sex, Eastern Cooperative Oncology Group (ECOG) stage, treatment regimen and number of cycles.
- Efficacy endpoints: progression free survival (PFS) and overall survival (OS).
- Safety: adverse effects (AEs), delays of therapy, reductions of doses and suspensions of treatment.
- Analysis: Kaplan–Meier curve (SPSS Statistics v.24 programme)

Results
- 41 patients
- Age 61.5 (47-79)
- 75.9% men and 24.1% women
- ECOG 0-1
- Scheme: 28 GemNab and 13 FOLFIRINOX
- Median number of cycles: 4 (1-14) in GemNab group and 6 (1-18) in FOLFIRINOX group

<table>
<thead>
<tr>
<th></th>
<th>GemNab</th>
<th>FOLFIRINOX</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS</td>
<td>8 months (95% CI, 4 to 11)</td>
<td>8 months (95% CI, 3 to 12)</td>
</tr>
<tr>
<td>OS</td>
<td>7 months (95% CI, 2 to 11)</td>
<td>8 months (95% CI, 3 to 12)</td>
</tr>
<tr>
<td>AEs</td>
<td>Asthenia (64.3%)</td>
<td>Neurotoxicity (38.5%)</td>
</tr>
<tr>
<td></td>
<td>Neurotoxicity (25%)</td>
<td>Diarrhoea (30.8%)</td>
</tr>
<tr>
<td></td>
<td>Diarrhoea (25%)</td>
<td>Neutropenia (23.1%)</td>
</tr>
<tr>
<td>Delays</td>
<td>60.7%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Reductions</td>
<td>60.7%</td>
<td>61.5%</td>
</tr>
<tr>
<td>Suspensions</td>
<td>17.9%</td>
<td>38.5%</td>
</tr>
</tbody>
</table>

Conclusion and relevance
- GemNab and FOLFIRINOX showed a similar effectiveness.
- More than half of the patients presented delays of therapy and reductions of doses in both groups and more patients discontinued treatment with the FOLFIRINOX regimen due to AEs.